# Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis

> **NCT03235752** · PHASE2 · COMPLETED · sponsor: **I-Mab Biopharma HongKong Limited** · enrollment: 91 (actual)

## Conditions studied

- Active Ulcerative Colitis

## Interventions

- **DRUG:** TJ301 300mg
- **DRUG:** TJ301 600mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03235752
- **Lead sponsor:** I-Mab Biopharma HongKong Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-06
- **Primary completion:** 2020-12-21
- **Final completion:** 2020-12-21
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03235752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03235752, "Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03235752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*